The genetic basis of major depressive disorder (MDD) has been investigated extensively, but the identification of MDD genes has been hampered by conflicting results from underpowered studies. We review all MDD case-control genetic association studies published before June 2007 and perform meta-analyses for polymorphisms that had been investigated in at least three studies. The study selection and data extraction were performed in duplicate by two independent investigators. The 183 papers that met our criteria studied 393 polymorphisms in 102 genes. Twenty-two polymorphisms (6%) were investigated in at least three studies. Seven polymorphisms had been evaluated in previous meta-analyses, 5 of these had new data available. Hence, we performed meta-analyses for 20 polymorphisms in 18 genes. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Statistically significant associations were found for the APOE e2 (OR, 0.51), GNB3 825T (OR, 1.38), MTHFR 677T (OR, 1.20), SLC6A4 44 bp Ins/Del S (OR, 1.11) alleles and the SLC6A3 40 bpVNTR 9/10 genotype (OR, 2.06). To date, there is statistically significant evidence for six MDD susceptibility genes (APOE, DRD4, GNB3, MTHFR, SLC6A3 and SLC6A4).
Introduction
Major depressive disorder (MDD) is the leading cause of disability for individuals of 15-44 years of age and is expected to be the second cause of disability worldwide for individuals of all ages by the year 2020. 1 MDD is caused by a complex interaction of a large number of genetic and non-genetic factors, each with a relatively small contribution to the disorder. 2 The total contribution of genetic factors in the origin of disease, the heritability, is estimated at 37%. 3 Firstdegree relatives of MDD patients have a 2-to 3-fold increased risk of MDD compared to the general population. 4 Since the first case-control study on the relationship between polymorphisms and depression in 1978, 5 many genetic association studies have been conducted. Nevertheless, this accumulation of research has not resulted in the identification of many MDD susceptibility genes, because the findings of the association studies have often been inconsistent. 4 A first explanation for these inconsistencies concern methodological differences between the studies, such as differences in study design, study population and MDD diagnostic criteria, which hamper the comparability of the studies. A second explanation is that many studies had small sample sizes and therefore insufficient statistical power to demonstrate statistically significant effects of these low-risk susceptibility genes. 6 The impact of the latter problem can be reduced by pooling single studies in meta-analyses. 7 To date, meta-analyses for MDD have been conducted for seven polymorphisms in six genes (Table 1) . These meta-analyses included the genes encoding for angiotensin I-converting enzyme (ACE), dopamine receptor D4 (DRD4), serotonin 5-HT-2A receptor (HTR2A), methylenetetrahydrofolate reductase (MTHFR), serotonin transporter (SLC6A4) and tyrosine hydroxylase (TH). [8] [9] [10] [11] [12] [13] [14] [15] The DRD4 gene was significantly associated to MDD (odds ratio (OR), 1.73; 95% confidence interval (CI), 1.29-2.32), 11 and the MTHFR was significantly associated to depression (OR, 1.36; CI, 1.11-1.67).
15 SLC6A4 44 bp Ins/Del is the most frequently studied polymorphism to date and has been evaluated in three previous metaanalyses. 8, 12, 13 The first meta-analysis, including only 275 patients, showed a statistically significant increased MDD risk for carriers of S allele (OR, 1.23), 13 but two subsequent larger meta-analyses were unable to confirm this finding. 8, 12 Many other genes have been studied in relation to MDD. Our aim is to review all case-control studies on the association between genetic polymorphisms and MDD and perform meta-analyses for polymorphisms that had been investigated in at least three studies.
Materials and methods

Data sources
We searched PubMed for genetic case-control association studies on MDD published before June 2007. The search strategy was based on the keywords unipolar depression, major depression, depressive disorder or affective disorder in combination with chromosome, gene, allele or polymorphism. A second search was carried out using the name of the genes identified in the first search in combination with a broader keyword search: unipolar, depression, depressive or affective. In addition, we searched the PubMed, HuGeNet, ISI Web of Science databases, the Genetic Association Database and the reference lists of the retrieved articles.
Study selection
Genetic association studies were selected if they had applied a case-control design and compared adults diagnosed with standard diagnostic criteria for MDD. Studies were excluded if (1) cases were selected by questionnaires assessing symptoms of depression, (2) the study population included bipolar patients, (3) the distribution of genotypes in the control population was not in Hardy-Weinberg equilibrium or (4) if the data were reused in a larger study on the same polymorphism. Study selection and data extraction were performed in duplicate by two independent investigators (SLL and AGZ) and discrepancies were discussed with a third investigator (ACJWJ).
Data synthesis
Meta-analyses were performed for polymorphisms that had been investigated in at least three studies. Published meta-analyses were updated when new studies were available. ORs were summarized using both random effects and fixed effects meta-analyses with 95% CIs as outlined by DerSimonian and Laird. 16 The degree of heterogeneity between the study results was assessed with the I 2 statistics. 17 Forest plots were obtained for meta-analyses with statistically significant results, presenting random effect meta-analyses if there was evidence of heterogeneity (I 2 > 50), 18 and fixed effects meta-analyses if there was no heterogeneity. Sources of heterogeneity were explored in sensitivity analyses by removing one study at a time and calculating pooled ORs on the remaining studies. Sensitivity analysis also examines the extent to which pooled ORs were determined by significant effects of the first published study. 6 Publication bias was evaluated by visual inspection of the funnel plots. 19 Cochrane Review Manager Version 4.2 was used for all statistical analyses. P < 0.05 (two-tailed) were considered statistically significant.
Results
Of the 215 articles that met our inclusion criteria, 32 were excluded. Five studies selected cases by questionnaires assessing symptoms of depression, [20] [21] [22] [23] [24] 9 studied MDD and bipolar depression without [34] [35] [36] [37] [38] [39] [40] [41] and 10 reported data that had later been reused in a larger study for the same polymorphism. [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] The remaining 183 articles studied 393 different polymorphisms in 102 genes (Figure 1 ). Of the 393 polymorphisms, 371 were investigated in one or two studies (Table 2) . Only 22 (6%) polymorphisms in 20 (19%) genes were investigated in more than 3 studies.
Of the 22 polymorphisms, 7 had been reviewed in previous meta-analyses, of which for 5 polymorphisms (ACE I/D, HTR2A T102C, MTHFR C677T, SLC6A4 VNTR and SLC6A4 44 bp Ins/Del) were new data available. Hence, we performed meta-analyses for 20 polymorphisms in 18 genes (Table 3) . Five polymorphisms showed statistically significant association to MDD: apolipoprotein E (APOE), guanine nucleotide-binding protein (GNB3) 825T, MTHFR 677T, dopamine transporter (SLC6A3) 40 bp VNTR, and the SLC6A4 44 bp Ins/Del ( Figure 2 ). Figure 3 shows the funnel plots for the statistically significant meta-analyses.
APOE
The APOE e2 allele was examined in 7 studies including a total of 827 cases and 1616 controls. [108] [109] [110] [111] [112] [113] [114] One study found a very strong protective effect for the e2 allele (OR, 0.06; CI, 0.02-0.21), 108 while the others showed moderate protective effects (OR varying from 0.45 to 1.03; Figure 2 ). The pooled OR of the e2 allele compared to the e3 allele was 0.51 (CI, 0.27-0.97). The per allele meta-analysis of studies in Caucasian populations also showed a statistically significant pooled OR (0.72; CI, 0.51-1.00) with no evidence for between-study heterogeneity. [109] [110] [111] [112] [113] There were not enough studies to perform a meta-analysis of only studies from Asian origin. The pooled OR of the e2 allele was not statistically significant when the first published study was removed from the analysis (OR, 0.51; CI, 0.25-1.05). 112 The funnel plot shows that the three smaller studies had lower ORs than the larger studies ( Figure 3 ), but that there was no convincing evidence for publication bias.
GNB3
The association between the GNB3 C825T polymorphism and MDD was investigated in 3 studies with a total of 375 cases and 492 controls. 44, 133, 134 All ORs in the individual studies were greater than 1. The per allele meta-analysis, testing for a trend by the number of T alleles, showed a significant effect of the T allele (OR, 1.38; CI, 1.13-1.69; Figure 2 ).
MTHFR
Six studies investigated the MTHFR C677T polymorphism in a total of 875 cases and 3859 controls. 15, [194] [195] [196] [197] [198] Five studies showed an increased MDD Figure 1 Selection of studies for the meta-analyses. *The number of genes does not add up to 102, because 8 genes were investigated for multiple polymorphisms of which some were addressed in more than three studies.
risk for homozygous carriers of the T allele, but in only one study this association was statistically significant (Figure 2 ). 194 The 
SLC6A3
The SLC6A3 40 bp VNTR polymorphism was investigated in 3 studies including a total of 151 cases and 272 controls. 121, 128 Each study showed an increased MDD risk for carriers of the 9/10 genotype compared to the 10/10 genotype, but only one study was statistically significant. 121 The pooled OR for the 9/ 10 genotype compared to the 10/10 genotype was 2.06 (CI, 1.25-3.40).
SLC6A4
Twenty-four studies investigated SLC6A4 44 bp Ins/Del short/long (S/L) polymorphism including a total of 3752 cases and 5707 controls. 13, 41, 55, 121, 151, 208, 209, 211, [213] [214] [215] [216] [221] [222] [223] [224] [225] [226] [227] [228] [229] Twenty of the individual studies reported an OR higher than 1 for the S allele vs the L allele, but only in three studies this association was statistically significant (Figure 2) . [214] [215] [216] The pooled OR for the S allele was 1.11 (CI, 1.04-1.19) and the pooled OR for homozygous carriers was 1.39 (CI, 1.20-1.61). When the first published study was removed, these ORs remained statistically significant (OR S vs L , 1.11; CI, 1.01-1.22, OR SS vs LL , 1.37; CI, 1.16-1.61). 55 The funnel plot shows asymmetry as 17 out of the 24 studies show a higher OR than the pooled estimate, but there was no evidence for publication bias toward studies with higher OR (Figure 3 ).
Other genes
The remaining meta-analyses were not significant, their ORs ranged from 0.74 to 0.99 for protective effects and from 1.09 to 1.63 for risk alleles/genotypes. Figure 4 shows the ORs in relation to the total number of cases and controls that were included in the meta-analyses. Fifteen out of 20 meta-analyses included less than 3000 subjects in total, of which 12 had less than 1000 cases. For example, the metaanalysis of DRD3 Ser9Gly polymorphism included 541 cases and 606 controls. The OR of the homozygous carriers was 1.71 and was not significant. In contrast, the meta-analysis of the SLC6A4 44 bp Ins/ Del polymorphism totalled more than 9000 persons and had a statistically significant OR of 1.11 for the S allele.
Discussion
In this review, we were able to perform meta-analyses for 18 out of 102 genes studied. We were not able to perform meta-analyses for 371 polymorphisms in 97 genes because there were less than three studies assessing the same polymorphism. We found significant evidence for five MDD susceptibility genes (APOE, GNB3, MTHFR, SLC6A3 and SLC6A4).
The identified genes are involved in known biological pathways. The dopamine transporter (SLC6A3) mediates the active reuptake of dopamine from the synapse and is a principal regulator of dopaminergic neurotransmission. All antidepressants, in one way or the other, affect dopamine in the frontal area of the brain and in the nucleus accumbens. [56] [57] [58] The protein encoded by the SLC6A4 gene is the drug target of serotonin reuptake inhibitors (SRIs) such as fluoxetine. 59 The 44 bp Ins/Del polymorphism is localized in the promotor region and may affect expression of the protein. 60 GNB3 encodes for the b-subunit of G proteins, which is a target for antidepressant medication such as tricycles and mono-aminoxidase inhibitors. 61 MTHFR is a plausible candidate since the MTHFR enzyme metabolizes folate, and lower folate levels have been found associated with depression. 63 Furthermore, recovery Numbers indicate the number of polymorphisms that were significantly associated to MDD out of the total number of different polymorphisms studied. Genes that were also included in the meta-analyses are here listed for other polymorphisms. a Concerns a genetic marker. References did not present complete information on genotype frequencies. Authors were contacted and all provided genotype data. from depression may be enhanced by folate supplements. 64 The most strongly associated gene in terms of the OR is APOE. APOE is recognized as a major determinant in lipoprotein metabolism, cardiovascular disease, Alzheimer's disease, cognitive function and immunoregulation; 65 and as each of these disorders may be implicated in MDD, APOE remains at least a conceivable candidate gene to be studied further. While these five genes were significantly associated to MDD in the meta-analyses, this does not mean the others may not be related. First, for many metaanalyses the total number of cases and controls studied was not large enough to detect moderate association to genes (OR B1.2-1.5). For example, the pooled ORs of DRD3, HTR1A and SLC6A4 VNTR in intron 2 were 1.33-1.71, but not statistically significant. In terms of genetic effects for complex diseases, these are not small effects. In addition to small sample size, other reasons for the absence of statistical significance are the low frequencies of the risk variant and heterogeneity between studies.
Second, most studies have investigated only one single polymorphism per gene. Even if this single polymorphism appears not to be associated, there may still be other variants in the gene that are associated to MDD. The present meta-analyses only included two genes for which two polymorphisms were investigated (HTR2A and SLC6A4). The 44 bp Ins/Del polymorphism of the SLC6A4 gene was found to be associated with MDD, while the VNTR intron 2 of SLC6A4 was not. The latter shows that a negative meta-analysis on one polymorphism does not rule out significant associations of other polymorphisms in the same gene.
Most research on the genetic origin of MDD has focussed on a limited number of polymorphisms. Meta-analyses could only be performed for 22 of the 393 (6%) polymorphisms that had been investigated in relation to MDD. There were 371 polymorphisms that were only addressed in one or two studies, while 13 studies investigating the HTR2C Cys23Ser polymorphism and 24 studies investigated the SLC6A4 44 bp Ins/Del polymorphism. SLC6A4 has been reviewed in three previous meta-analyses, 8, 12, 13 two showing no evidence for association with MDD.
Differences between the meta-analyses may be explained by the inclusion of different studies, by heterogeneity between the results of individual studies, or by underestimation of effect sizes due to bi-allelic (S/L) instead of tri-allelic (S/L G /L) grouping of the genotypes. The tri-allelic grouping distinguishes two long alleles (L G /L), while the L G expresses similar to the S allele. 60 The high numbers of studies of these polymorphisms are exceptions. For most polymorphisms reviewed in the meta-analyses the number of available studies was still small, and most meta-analyses did not include enough studies to investigate sources of heterogeneity in a meta-regression, or perform formal tests of publication bias. Meta-regression analysis would be useful to investigate whether the asymmetric funnel plots of the SLC6A4 44 bp Ins/Del and APOE e2 are suggestive of publication bias or indicate true heterogeneity between populations. This review clearly demonstrates that more MDD genetic association studies are needed.
We excluded studies if they used questionnaires for the identification of cases, if they did not distinguish between MDD and bipolar depression, or if the genotype distributions in controls were not in Hardy-Weinberg equilibrium. Yet, we did not exclude studies or stratify the analyses based on other criteria, for example, whether controls were selected from the general population or whether they had been screened for the absence of depression, because the number of studies for each polymorphism was small. Such differences between studies may have contributed to the heterogeneity that was found in several of the meta-analyses. To investigate causes of between-study heterogeneity in future meta-analyses, it is essential that individual studies report key characteristics of their populations. To accumulate the evidence in genetic-epidemiological studies harmonizing designs, populations and measurements is deemed important and aimed for by the Network of Investigator Networks of the Human Genome Epidemiology Network. 66 In conclusion, our meta-analyses found significant evidence for five MDD susceptibility genes (APOE, GNB3, MTHFR, SLC6A3 and SLC6A4). Together with our previously published meta-analysis on DRD4, 11 there is evidence for six MDD susceptibility genes. The low coverage of genetic variants of candidate genes makes it impossible to exclude that the other genes studied are not involved in MDD. More research aiming to replicate findings in MDD is needed and efforts are required to standardize the methodology in research of MDD. 
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